Role for amplification and expression of Glypican-5 in rhabdomyosarcoma

Cancer Research

Volumn 67, Issue 1, 2007, Pages 57-65

  Williamson, Daniel ^a   Selfe, Joanna ^a   Gordon, Tony ^a   Lu, Yong Jie ^a   Pritchard Jones, Kathy ^a   Murai, Kasumi ^b   Jones, Phil ^b   Workman, Paul ^a   Shipley, Janet ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; PROTEIN GLYPICAN 5; PROTEIN S 100; SCATTER FACTOR; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ARTICLE; BLASTOCYST; CANCER GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMOSOME 13Q; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; GENE NUMBER; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRAIT; HUMAN; HUMAN CELL; MESODERM; PRIORITY JOURNAL; PROMOTER REGION; RHABDOMYOSARCOMA; XENOPUS;

AMINO ACID SEQUENCE; ANIMALS; CELL GROWTH PROCESSES; CELL MEMBRANE; CHROMOSOMES, HUMAN, PAIR 13; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GLYPICANS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICROINJECTIONS; MICRORNAS; MOLECULAR SEQUENCE DATA; RHABDOMYOSARCOMA; RNA; SIGNAL TRANSDUCTION; XENOPUS LAEVIS;

EID: 33846416922     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1650     Document Type: Article

References (44)

1. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
2. Anderson J, Gordon A, Pritchard-Jones K, Shipley J. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosomes Cancer 1999;26:275-85.
3. Weber-Hall S, Anderson J, McManus A, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 1996;56:3220-4.
4. Gordon AT, Brinkschmidt C, Anderson J, et al. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 2000;28:220-6.
5. Lu YJ, Williamson D, Clark J, et al. Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. Proc Natl Acad Sci U S A 2001;98:9197-202.
6. Knuutila S, Autio K, Aalto Y. Online access to CGH data of DNA sequence copy number changes. Am J Pathol 2000;157:689.
7. Schmidt H, Bartel F, Kappler M, et al. Gains of 13q are correlated with a poor prognosis in liposarcoma. Mod Pathol 2005;18:638-44.
8. Neat MJ, Foot N, Jenner M, et al. Localisation ol a novel region of recurrent amplification in follicular lymphoma to an approximately 6.8 Mb region of 13q32-33. Genes Chromosomes Cancer 2001;32:236-43.
9. Ullmann K, Petzmann S, Sharma A, et al. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol 2001;32:1059-63.
10. Ojopi EP, Rogatto SR, Caldeira JR, et al. Comparative genomic hybridization detects novel amplifications in fibroadenomas of the breast. Genes Chromosomes Cancer 2001;30:25-31.
11. Reardon DA, Jenkins JJ, Sublett JE, et al. Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastuma. Pediatr Neurosurg 2000;32:187-91.
12. Williamson D, Lu YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005;23:880-8.
13. McManus AP, O'Reilly MA, Jones KP, et al. Interphase fluorescence in situ hybridization detection of t(2:13) (q35;q14) in alveolar rhabdomyosarcoma-a diagnostic tool in minimally invasive biopsies. J Pathol 1996;178:410-4.
14. Ota A, Tagawa H, Karnan S, et al. Identificalion and characterization of a novel gene, C13orf25, as a target for 13q31-32 amplification in malignant lymphoma. Cancer Res 2004;64:3087-95.
15. Veugelers M, Vermeesch J, Reekmans G, et al. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics 1997;40:24-30.
16. Saunders S, Paine-Saunders S, Lander AD. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev Biol 1997;190:78-93.
17. Landegren U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 1984;67:379-88.
18. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
19. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
20. Holland EC, Sonenberg N, Pandolfi PP, et al. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 2004;23:3138-44.
21. Williamson D, Lu Y, Fang C, et al. Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 2006;45:839-45.
22. Treisman R. The serum response element. Trends Biochem Sci 1992;17:423-6.
23. Galli A, Roure A, Zeller R, et al. Glypican 4 modulates FGF signaling and regulates dorsoventral forebrain patterning in Xenopus embryos. Development 2003;130:4919-29.
24. Yu W, Inoue J, Imoto I, et al. GPC5 is a possible target for the 13q31-32 amplification detected in lymphoma cell lines. J Hum Genet 2003;48:331-5.
25. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
26. Shih Ie M, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma Proc Natl Acad Sci U S A 2005;102:14004-9.
27. Kleeff J, Ishiwata T, Kumbasar A, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998;102:1662-73.
28. Matsuda K, Maruyama H, Guo F, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 2001;61:5562-9.
29. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000;89:418-22.
30. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-21.
31. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
32. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-65.
33. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12:241-7.
34. Ibrahimi OA, Zhang F, Hrstka SC, et al. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 2004;43:4724-30.
35. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65:6245-54.
36. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991;291:229-32.
37. Schweigerer L, Neufeld G, Mergia A, et al. Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors. Proc Natl Acad Sci U S A 1987;84:842-6.
38. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003;63:7926-35.
39. Pirskanen A, Kiefer JC, Hauschka SD. IGFs, insulin, Shh, bFGF, and TGF-β1 interact synergistically to promote somite myogenesis in vitro. Dev Biol 2000; 224:189-203.
40. Bandow K, Ohnishi T, Tamura M, et al. Hepatocyte growth factor/scatter factor stimulates migration of muscle precursors in developing mouse tongue. J Cell Physiol 2004;201:236-43.
41. Snider L, Tapscott SJ. Emerging parallels in the generation and regeneration of skeletal muscle. Cell 2003;113:811-2.
42. Liu X, McFarland DC, Nestor KE, et al. Developmental expression of skeletal muscle heparan sulfate proteoglycans in turkeys with different growth rates. Poult Sci 2002;81:1621-8.
43. Chu CL, Buczek-Thomas JA, Nugent MA. Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Biochem J 2004;379:331-41.
44. Motomura Y, Senju S, Nakatsura T, et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-10. Cancer Res 2006;66:2414-22.